Feature | January 31, 2012 | Helen Kuhl

The Impact of IMRT

Intensity-modulated radiation therapy is a complex but valuable treatment option.

Intensity modulated radiation therapy (IMRT) emerged as a new way to treat patients in the late 1990s and garnered attention because it offered the possibility to avoid radiating healthy tissue with more accuracy than conventional radiation therapy techniques. As a highly conformal 3-D therapy, its precise targeting of a tumor allows higher radiation doses to be delivered more safely. Since its inception, it has grown especially in use for cancers in the prostate, head and neck regions, as well as other areas of the body.

Its impact has been widespread. Radiation Medical Group in San Diego, Calif., says on its website that IMRT is “the single biggest improvement in radiation therapy in the last 30 years. It is very much like going from the propeller age to the jet age in aviation.” (www.rmg.md/IMRT.htm)

Varian, Accuray and Elekta are the primary vendors of linac technology to perform IMRT. Varian, Elekta, Philips and RaySearch offer treatment planning software, which is a critical part of the IMRT process. It is an involved and time-consuming process to create a treatment plan for IMRT and achieve the 3-D conformity. The International RadioSurgery Association (IRSA) estimates an IMRT treatment plan takes an average of two to three days per patient (www.irsa.org/imrt.html).

Because the IMRT process is complex and the doses are so high, there are more opportunities for error, so safety is a concern. In fact, the American Society for Radiation Oncology (ASTRO) kicked off a recent series of white papers addressing patient safety with “Safety Considerations for IMRT,” published in July 2011 in Practical Radiation Oncology. (www.practicalradonc.org/article/S1879-8500(11)00162-7/fulltext)

“This report provides an opportunity to broadly address safe delivery of IMRT, with a primary focus on recommendations for human error prevention and methods to reduce the occurrence of errors or machine malfunctions that can lead to catastrophic failures or errors,” the report introduction said. The document includes tools and techniques to be used by clinics to ensure the safety of their IMRT programs.

Environmental and Technical Safety Concerns
The ASTRO white paper classifies safety hazards for IMRT into two groups: environmental and technical.

Environmental concerns are not unique to IMRT, but have safety implications for many other types of treatment. They include: lack of standard operating procedures, haste (i.e., inadequate time to perform all steps in a process), habituation, incomplete understanding or misuse of procedure/equipment, an inadequate QA program and lack of continuing staff education.

The technical concerns are areas such as inadequate commissioning of the clinical IMRT program, inadequate validation of the accuracy of treatment delivery parameters, improper use of one or more parts of the planning and delivery process, and inadequate investigation of discrepancies between treatment plan parameters and QA results. The white paper presents detailed recommendations and step-by-step guidelines to facilitate a safe IMRT program. (ASTRO also is in the process of developing two more white papers as part of its series, on peer review and image-guided radiation therapy. These can have an effect on IMRT practices as well.)

Customers Adopt New Technology
According to a report from KLAS, “Radiation Therapy 2011: A Dose of New Technology,” released last November, the oncology market in general has been growing. That trend is expected to continue, thanks to the need created by an aging population, and despite the slow economy and cuts in Medicare reimbursements.

“Providers are buying, and new vendors are entering the market,” KLAS said.

The report evaluated customer satisfaction with equipment and treatment planning software used for radiation therapy, including IMRT, as well as their concerns. It noted that radiation therapy providers are anxious to have the latest technology for treatment reasons, but also as a marketing tool. “The biggest provider draw is bleeding-edge technology, not only for patients’ benefit, but also for marketing and referrals,” the report stated.

Customers also are concerned with the safety of their systems, especially as patients read negative publicity about radiation dose. They believe their systems to be safe, but look for help with safety education from their vendors.

Reliability is another key factor for customers, who want a system with minimal downtime. “Providers are really looking for reliable equipment that is technologically advanced that they are able to draw referrals on. The combination of those attributes is driving satisfaction in the oncology market,” said the report.

For additional information, visit www.KLASresearch.com.

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...